ENTRY       D10900            Mixture   Drug
NAME        Sofosbuvir, velpatasvir and voxilaprevir;
            Vosevi (TN)
PRODUCT     VOSEVI (Gilead Sciences)
COMPONENT   Sofosbuvir [DR:D10366], Velpatasvir [DR:D10806], Voxilaprevir [DR:D10899]
CLASS       Antiviral
             DG03198  Anti-HCV agent
REMARK      ATC code: J05AP56
            Product: D10900<US>
EFFICACY    Antiviral
  DISEASE   Chronic hepatitis C virus infection [DS:H00413]
TARGET      HCV NS3/4A protease [KO:K22273 K22274]
            HCV NS5A [KO:K22275]
            HCV NS5B [KO:K22472]
  PATHWAY   ko03230(K22273+K22274+K22275+K22472)  Viral genome structure
            ko03240(K22273+K22274+K22275+K22472)  Viral replication
            ko05160(K22273+K22274+K22275+K22472)  Hepatitis C
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP56 Sofosbuvir, velpatasvir and voxilaprevir
                  D10900  Sofosbuvir, velpatasvir and voxilaprevir &lt;US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis C (HCV) Agents
               Sofosbuvir/ Velpatasvir/ Voxilaprevir
                D10900  Sofosbuvir, velpatasvir and voxilaprevir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10900  Sofosbuvir, velpatasvir and voxilaprevir
            Drug classes [BR:br08332]
             Antiviral
              DG03198  Anti-HCV agent
               D10900  Sofosbuvir, velpatasvir and voxilaprevir
            Antimicrobials [BR:br08307]
             Antivirals
              Polyprotein cleavage inhibitor
               HCV NS3/4A inhibitor
                D10900  Sofosbuvir, velpatasvir and voxilaprevir &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10900
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10900
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10900
DBLINKS     PubChem: 340650304
///
